Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer
2005 ◽
Vol 23
(16_suppl)
◽
pp. 7099-7099
◽
Keyword(s):
Phase Ii
◽